Technical Analysis for INSY - Insys Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
INSY closed up 3.92 percent on Friday, December 8, 2017, on 1.68 times normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
|See historical INSY trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 8||50 DMA Resistance||Bearish||0.00%|
|Dec 8||Shooting Star Candlestick||Bearish||0.00%|
|Dec 8||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Dec 8||New Uptrend||Bullish||0.00%|
|Dec 8||Wide Bands||Range Expansion||0.00%|
|Dec 8||Above Upper BB||Strength||0.00%|
|Dec 7||1,2,3 Retracement Bearish||Bearish Swing Setup||3.92%|
|Dec 7||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||3.92%|
|Dec 7||Weak + Overbought||Other||3.92%|
|Dec 7||BB Squeeze Ended||Range Expansion||3.92%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more INSY news...
|52 Week High||15.02|
|52 Week Low||4.1|
|200-Day Moving Average||9.9101|
|50-Day Moving Average||6.4052|
|20-Day Moving Average||5.3125|
|10-Day Moving Average||5.416|
|Average True Range||0.4276|
|Chandelier Exit (Long, 3 ATRs )||5.2972|
|Chandelier Exit (Short, 3 ATRs )||6.1828|
|Upper Bollinger Band||5.7837|
|Lower Bollinger Band||4.8413|
|Percent B (%b)||1.33|
|MACD Signal Line||-0.3266|
|Market Cap||442.72 Million|
|Num Shares||72.7 Million|
|Price-to-Earnings (P/E) Ratio||-27.68|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.08|
|Resistance 3 (R3)||7.13||6.86||6.92|
|Resistance 2 (R2)||6.86||6.60||6.83||6.86|
|Resistance 1 (R1)||6.47||6.45||6.67||6.42||6.80|
|Support 1 (S1)||5.81||5.94||6.01||5.76||5.38|
|Support 2 (S2)||5.54||5.79||5.51||5.32|
|Support 3 (S3)||5.15||5.54||5.27|
|Support 4 (S4)||5.10|